Aims: Analysis of pre-operative spectral domain optical coherence tomography (SD-OCT) characteristics of full-thickness macular holes (FTMH) and effect on optimum management. Methods: We retrospectively reviewed SD-OCT characteristics of a consecutive cohort of patients waitlisted for FTMH surgery and categorized them by current evidence-based treatments. Results: Out of the 106 holes analysed, 36 were small, 40 medium and 30 large. Initially, 33 holes had vitreomacular adhesion (VMA). 41 holes were analysed for change in characteristics with a median duration of 8 weeks between the scans. The number of small or medium holes decreased from 20 to 6 and that of large holes doubled. The number of holes with VMA halved. Smaller hole size (p = 0.014) and being phakic (p = 0.048) were associated with a larger increase in size. The strongest predictor of hole progression into a different surgical management category was the presence of VMA. Conclusion: FTMH characteristics can change significantly pre-operatively and affect optimal treatment choice.

Keywords:
Macular hole, Vitreomacular attachment, Vitrectomy, Ocriplasmin
1.
Stalmans P, Benz M, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA: Enzymatic vitreolysis with ocriplasmin for vitreamacular traction and macular holes; MIVI-TRUST Study Group. N Engl J Med 2012;367:606-615.
2.
Steel DHW, Lotery AJ: Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis and treatment. Eye (Lond) 2013;27(suppl 1):S1-S21.
3.
Spiteri Cornish K, Lois N, Scott N, Burr J, Cook J, Boachie C, Tadayoni R, la Cour M, Christensen U, Kwok A: Vitrectomy with internal limiting membrane (ILM) peeling versus vitrectomy with no peeling for idiopathic full-thickness macular hole (FTMH). Cochrane Database Syst Rev 2013;6:CD009306.
4.
Tadayoni R, Gaudric A, Haouchine B, Massin P: Relationship between macular hole size and the potential benefit of internal limiting membrane peeling. Br J Ophthalmol 2006;90:1239-1241.
5.
Solebo AL, Lange CA, Bunce C, Bainbridge JW: Face-down positioning or posturing after macular surgery. Cochrane Database Syst Rev 2011;12:CD008228.
6.
Guillaubey A, Malvitte L, Lafontaine PO, Jay N, Hubert I, Bron A, Creuzot-Garcher C: Comparison of face-down and seated position after idiopathic macular hole surgery: a randomized clinical trial. Am J Ophthalmol 2008;146:128-134.
7.
Lange CA, Membrey L, Ahmad N, Wickham L, Maclaren RE, Solebo L, Xing W, Bunce C, Ezra E, Charteris D, Aylward B, Yorston D, Greor Z, Zambarakji H, Bainbridge JW: Pilot randomised controlled trial of face-down positioning following macular hole surgery. Eye (Lond) 2012;26:272-277.
8.
Chew EY, Sperduto RD, Hiller R, Nowroozi L, Seigel D, Yanuzzi LA, Burton TC, Seddon JM, Gragoudas ES, Haller JA, Blair NP, Farber M: Clinical course of macular holes: the Eye Disease Case-Control Study. Arch Ophthalmol 1999;117:242-246.
9.
DeCroos FC, Toth CA, Folgar FA, Pakola S, Stinnett SS, Heydary CS, Burns R, Jaffe GJ: Characterisation of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin. Invest Ophthalmol Vis Sci 2012;53:6504-6511.
10.
Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P: The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013;120:2611-2619.
11.
Gass JDM: Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol 1995;119:752-759.
12.
Moisseiev J, Moroz J, Katz G: Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin. JAMA Ophthalmol 2014;132:709-713.
13.
Tadayoni R, Svorenova I, Erginay A, Gaudric A, Massin P: Decreased retinal sensitivity after internal limiting membrane peeling for macular hole surgery. Br J Ophthalmol 2012;96:1513-1516.
14.
Lois N, Burr J, Norrie J, Vale L, Cook J, McDonald A, Boachie C, Ternent L, McPherson G: Internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole: a pragmatic randomized controlled trial. Invest Ophthalmol Vis Sci 2011;52:1586-1592.
15.
Wakely L, Rahman R, Stephenson J: A comparison of several methods of macular hole measurement using optical coherence tomography and their value in predicting anatomical and visual outcomes. Br J Ophthalmol 2012;96:1003-1007.
16.
Nadal J, Delas B, Pinero A: Vitrectomy without face-down posturing for idiopathic macular holes. Retina 2012;32:918-921.
17.
Rahman R, Magdula I, Khan K: Outcomes of sulphur hexafluoride (SF6) versus perfluoroethane (C2F6) gas tamponade for non-posturing macular hole surgery. Br J Ophthalmol 2012;96:185-188.
18.
Kim SS, Smiddy WE, Feuer WJ, Shi W: Outcomes of sulphur hexafluoride (SF6) versus perfluoropropane (C3F8) gas tamponade for macular hole surgery. Retina 2008;28:1408-1415.
19.
Bainbridge J, Herbert E, Gregor Z: Macular holes: vitreoretinal relationships and surgical approaches. Eye (Lond) 2008;22:1301-1309.
20.
Yorston D, Siddiqui MA, Awan MA, Walker S, Bunce C, Bainbridge JW: Pilot randomised controlled trial of face-down posturing following phacovitrectomy for macular hole. Eye (Lond) 2011;26:267-271.
21.
Alberti M, la Cour M: Face-down positioning versus non-supine positioning in macular hole surgery. Br J Ophthalmol 2015;99:236-239.
22.
Aaberg TM, Blair CJ, Gass JDM: Macular holes. Am J Ophthalmol 1970;69:555-562.
23.
Freeman WR, Azen SP, Kim JW: Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentred randomised clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group. Arch Ophthalmol 1997;115:11-21.
24.
Morgan C, Schatz H: Idiopathic macular holes. Am J Ophthalmol 1985;99:437-444.
25.
McDonnell PJ, Fine SL, Hillis Al: Clinical features of idiopathic macular cysts and holes. Am J Ophthalmol 1982;93:777-786.
26.
Kim JW, Freeman WR, El-Haig W, Maguire AM, Arevalo JF, Azen SP: Baseline characteristics, natural history, and risk factors to progression in eyes with stage 2 macular holes. Results from a prospective randomised clinical trial. Vitrectomy for Macular Hole Study Group. Ophthalmology 1995;102:1818-1829.
27.
Hikichi T, Yoshida A, Akiba J, Trempe CL: Natural outcomes of stage 1, 2, 3, and 4 idiopathic macular holes. Br J Ophthalmol 1995;79:517-520.
28.
Casuso LA, Scott IU, Flynn HW, Gass DM, Smiddy WE, Lewis ML, Schiffman J: Long-term follow-up of unoperated macular holes. Ophthalmology 2001;108:1150-1155.
29.
Johnson RN, Gass JDM: Idiopathic macular hole. Observations, stages of formation, and implications for surgical intervention. Ophthalmology 1988;95:917-924.
30.
Privat E, Tadyoni R, Gaucher D, Haouchine B, Massin P, Gaudric A: Residual defect in the foveal photoreceptor layer detected by optical coherence tomography in eyes with spontaneously closed macular holes. Am J Ophthalmol 2007;143:814-819.
31.
Yuzawa M, Watanabe A, Takahashi Y, Matsui M: Observation of idiopathic full-thickness macular holes. Follow-up observation. Arch Ophthalmol 1994;112:1051-1056.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.